Trial Profile
Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination in Subjects With Hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/amlodipine/hydrochlorothiazide (Primary) ; Olmesartan medoxomil/amlodipine
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 29 Aug 2012 54-Week results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
- 29 Apr 2012 Analysis comparing efficacy in different age and gender groups presented at the 22nd European Meeting on Hypertension.
- 29 Apr 2012 Long-term results at 54 weeks presented at the 22nd European Meeting on Hypertension.